Loading
Adipokines, Inflammation, and Metabolic Diseases · Journal article
Frontiers in Genetics · August 6, 2026
Raises a question worth testing. It does not answer one.
This integrative genomic study explores shared and divergent molecular mechanisms linking depression and obesity using Mendelian randomization and single-cell transcriptomics. Evidence for directionality is inconclusive (MDD to obesity nominally significant but reverse association underpowered), and findings are positioned as hypothesis-generating rather than confirmatory, with candidate genes and drug targets requiring experimental validation.
Integrative multi-omics study combining epidemiological regression, bidirectional Mendelian randomization, summary-data-based MR with HEIDI testing, and single-cell RNA sequencing. National Health and Nutrition Examination Survey (NHANES) participants for epidemiological analysis; East Asian genetic data used for MR; regulatory T cells (Tregs) for scRNA-seq. Intervention: No intervention; observational and computational analysis of genetic and transcriptomic associations. Compared with: Bidirectional comparison of MDD-to-obesity versus obesity-to-MDD genetic associations. NHANES (United States) and East Asian genetic data; specific geographic sources for genetic cohorts not detailed.
Bidirectional MR from MDD to obesity risk: β = 0.0458, P = 0.0209 (nominally significant); reverse path inconclusive due to low statistical power (<10%) SMR/HEIDI identified FDR-significant obesity-associated genes including NT5C2, ACYP2, and TMEM180; depression-side only ACAT1 reached nominal significance Cell composition adjustment preserved up to 98% of effect sizes for top candidates, suggesting intrinsic remodeling rather than compositional shifts
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These findings do not yet support clinical practice changes. Clinicians should view this as preliminary hypothesis generation about potential shared molecular mechanisms; the convergent downstream pathways and nominated drug candidates (FDFT1, ADORA2A) require experimental validation before consideration for therapeutic repurposing.
This is an exploratory multi-omics study generating mechanistic hypotheses about shared genetic pathways in depression and obesity, with inconclusive bidirectional evidence and candidate genes requiring experimental validation.
As stated by the source record.
Quoted from the source exactly as published.
These findings do not yet support clinical practice changes. Clinicians should view this as preliminary hypothesis generation about potential shared molecular mechanisms; the convergent downstream pathways and nominated drug candidates (FDFT1, ADORA2A) require experimental validation before consideration for therapeutic repurposing.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Introduction Major depressive disorder (MDD) and obesity are intersecting global crises. Despite observational links, a clinical paradox persists: antidepressants often improve metabolic status, while weight loss rarely alleviates core depressive symptoms. This prompts closer examination of whether the depression–obesity relationship reflects asymmetric genetic architecture, shared liability, or statistical constraints that obscure definitive conclusions. Methods We developed an integrative multi-omics framework leveraging large-scale population data from the National Health and Nutrition Examination Survey (NHANES) and East Asian genetic data. Epidemiological regression was applied to NHANES to characterize real-world phenotypic cross-talk. We utilized bidirectional Mendelian randomization (MR) to explore the direction of association, targeted summary-data-based MR (SMR) with heterogeneity in dependent instruments (HEIDI) testing to prioritize candidate functional genes, and single-cell RNA sequencing (scRNA-seq) of regulatory T cells (Tregs). In silico cell composition adjustment and virtual knockout (VKO) simulations were implemented to distinguish intrinsic cellular remodeling from compositional shifts and to infer convergent downstream programs. Results Bidirectional MR yielded a nominally significant association from MDD to obesity risk (β = 0.0458, P = 0.0209), whereas the reverse path was inconclusive due to low statistical power ( 10%), precluding definitive conclusions about directionality. SMR/HEIDI identified multiple FDR-significant obesity-associated genes, including NT5C2, ACYP2, and TMEM180, whereas on the depression side only ACAT1 reached nominal significance, positioning it as a borderline hypothesis-generating candidate. Cell composition adjustment suggested that transcriptional signals reflected intrinsic remodeling, preserving up to 98% of effect sizes for top candidates. At the molecular level, the conditions diverged: obesity risk was dominated by immune-compartment inflammation and post-transcriptional splicing dysregulation, whereas MDD risk was characterized by ribosomal translation perturbations. Strikingly, VKO simulations revealed convergence on a shared downstream program anchored in cytoskeletal reorganization and E2F-target modulation. Exploratory druggability screening nominated FDFT1 (with a phase 3 inhibitor) and ADORA2A as potential repurposing candidates requiring experimental validation. Conclusion Our findings provide a hypothesis-generating reframing of the traditional comorbidity model, suggesting that divergent molecular programs may converge on shared pathways. Although the full extent of bidirectional genetic relationships remains unconfirmed, these findings offer a preliminary foundation for exploring therapeutic strategies at the mood–metabolism interface.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.